<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T03:09:16Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/101546" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/101546</identifier><datestamp>2025-12-10T00:52:57Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478917</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:Item id="hdl_2445_101546">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:2445/101546</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Whole genome sequencing to evaluate the resistance landscape&#xd;
                following antimalarial treatment failure with&#xd;
                fosmidomycin-clindamycin</dc:title>
               <dc:creator>Guggisberg, Ann M.</dc:creator>
               <dc:creator>Sundararaman, Sesh A.</dc:creator>
               <dc:creator>Lanaspa, Miguel</dc:creator>
               <dc:creator>Moraleda Redecilla, Cinta</dc:creator>
               <dc:creator>González, Raquel</dc:creator>
               <dc:creator>Mayor Aparicio, Alfredo Gabriel</dc:creator>
               <dc:creator>Cisteró, Pau</dc:creator>
               <dc:creator>Hutchinson, David</dc:creator>
               <dc:creator>Kremsner, Peter G.</dc:creator>
               <dc:creator>Hahn, Beatrice H.</dc:creator>
               <dc:creator>Bassat Orellana, Quique</dc:creator>
               <dc:creator>Odom, Audrey R.</dc:creator>
               <dc:subject>Malària</dc:subject>
               <dc:subject>Plasmodium falciparum</dc:subject>
               <dc:subject>Vacuna de la malària</dc:subject>
               <dc:subject>Malaria</dc:subject>
               <dc:subject>Plasmodium falciparum</dc:subject>
               <dc:subject>Malaria vaccine</dc:subject>
               <dc:description>Novel antimalarial therapies are needed in the face of emerging&#xd;
                resistance to artemisinin combination therapies. A previous&#xd;
                study found a high cure rate in Mozambican children with&#xd;
                uncomplicated Plasmodium falciparum malaria 7 days post&#xd;
                treatment with a fosmidomycin-clindamycin combination. However,&#xd;
                28-day cure rates were low (45.9%), due to parasite&#xd;
                recrudescence. We sought to identify any genetic changes&#xd;
                underlying parasite recrudescence. To this end, we utilized a&#xd;
                selective whole genome amplification method to amplify parasite&#xd;
                genomes from blood spot DNA samples. Parasite genomes from&#xd;
                pre-treatment and post-recrudescence samples were subjected to&#xd;
                whole genome sequencing to identify nucleotide variants. We find&#xd;
                that our data do not support the existence of a genetic change&#xd;
                responsible for recrudescence following fosmidomycin-clindamycin&#xd;
                treatment. Additionally, we find that previously described&#xd;
                resistance alleles for these drugs do not represent biomarkers&#xd;
                of recrudescence. Future studies should continue to optimize&#xd;
                fosmidomycin combinations for use as antimalarial therapies.</dc:description>
               <dc:date>2016-09-05T12:52:52Z</dc:date>
               <dc:date>2017-07-20T22:01:24Z</dc:date>
               <dc:date>2016-07-20</dc:date>
               <dc:date>2016-08-03T18:01:09Z</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/acceptedVersion</dc:type>
               <dc:relation>Versió postprint del document publicat a:&#xd;
                http://dx.doi.org/10.1093/infdis/jiw304</dc:relation>
               <dc:relation>The Journal of Infectious Diseases, 2016,</dc:relation>
               <dc:relation>http://dx.doi.org/10.1093/infdis/jiw304</dc:relation>
               <dc:rights>(c) Guggisberg et al., 2016</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>Oxford University Press</dc:publisher>
               <dc:source>Articles publicats en revistes (ISGlobal)</dc:source>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>